

SARS2 Antibody (Center) Blocking Peptide
Synthetic peptide
Catalog # BP7837c**Specification**

SARS2 Antibody (Center) Blocking Peptide - Product InformationPrimary Accession [Q9NP81](#)**SARS2 Antibody (Center) Blocking Peptide - Additional Information****Gene ID** 54938**Other Names**

Serine--tRNA ligase, mitochondrial, SerRSmt, Seryl-tRNA synthetase, SerRS, Seryl-tRNA(Ser/Sec) synthetase, SARS2, SARSM

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP7837c](/products/AP7837c) was selected from the Center region of human SARS2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

SARS2 Antibody (Center) Blocking Peptide - Protein Information**Name** SARS2**Synonyms** SARSM**Function**

Catalyzes the attachment of serine to tRNA(Ser). Is also probably able to aminoacylate tRNA(Sec) with serine, to form the misacylated tRNA L-seryl-tRNA(Sec), which will be further converted into selenocysteinyl-tRNA(Sec).

Cellular Location

Mitochondrion matrix {ECO:0000250|UniProtKB:Q9N0F3}

SARS2 Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

SARS2 Antibody (Center) Blocking Peptide - Images

SARS2 Antibody (Center) Blocking Peptide - Background

SARS2 catalyzes the attachment of serine to tRNA(Ser). It is also able to aminoacylate tRNA(Sec) with serine, to form the misacylated tRNA L-seryl-tRNA(Sec), which will be further converted into selenocysteinyl-tRNA(Sec).

SARS2 Antibody (Center) Blocking Peptide - References

Muller,T., Acta Neuropathol. 110 (4), 426-430 (2005)Gibbons,W.J. Jr., Biochem. Biophys. Res. Commun. 317 (3), 774-778 (2004)Yokogawa,T., J. Biol. Chem. 275 (26), 19913-19920 (2000)